Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05711940 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 94 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary completion moved earlier from Feb 2026 to Nov 13, 2025 Site details revised at 1 of 116 sitesv94 Show 1 more changeShow less
    • Site details revised at 1 of 116 sites
  2. 2 versions Re-verified since Dec 2, 2025, no change to tracked fieldsv92-v93
  3. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 568 to confirmed 572 · Study sites: 118 to 116v91 Show 2 more changesShow less
    • Enrollment target: estimated 568 to confirmed 572
    • Study sites: 118 to 116
  4. Site details revised at 15 of 118 sitesv90
  5. Site details revised at 14 of 118 sitesv89
Show 44 earlier versionsHide 44 earlier versions
  1. Study sites: 117 to 118v88
  2. Study sites: 116 to 117v87
  3. Study sites: 115 to 116v86
  4. Study sites: 114 to 115v85
  5. Study sites: 113 to 114v84
  6. Site contacts updated at 12 of 113 sitesv83
  7. Study sites: 110 to 113v82
  8. Study sites: 109 to 110v81
  9. Study sites: 108 to 109v80
  10. Study sites: 96 to 108v79
  11. Site details revised at 1 of 96 sitesv78
  12. Study description expanded, about 46 wordsv77 See this version in full on ClinicalTrials.gov ↗
  13. Study sites: 94 to 96v76
  14. Primary completion date: Mar 2025 to Feb 2026 Study sites: 86 to 94 · Completion date: May 2025 to Dec 2026v75 Show 2 more changesShow less
    • Study sites: 86 to 94
    • Completion date: May 2025 to Dec 2026
  15. Study sites: 84 to 86v74
  16. Site contacts updated at 1 of 84 sitesv73
  17. Study sites: 83 to 84v72
  18. Site details revised at 1 of 83 sitesv71
  19. Study sites revised (83)v70 See this version in full on ClinicalTrials.gov ↗
  20. Study sites: 82 to 83v69
  21. Study sites: 81 to 82v68
  22. Site details revised at 1 of 81 sitesv67
  23. Study sites: 77 to 81v66
  24. Site details revised at 4 of 77 sitesv65
  25. Site details revised at 1 of 77 sitesv64
  26. Site contacts updated at 3 of 77 sitesv63
  27. Study sites: 75 to 77v62
  28. Site details revised at 1 of 75 sitesv61
  29. Site contacts updated at 2 of 75 sitesv60
  30. Site contacts updated at 1 of 75 sitesv59
  31. Study sites: 67 to 75v58
  32. Site contacts updated at 2 of 67 sitesv57
  33. Site contacts updated at 1 of 67 sitesv56
  34. Site details revised at 1 of 67 sitesv55
  35. Study sites: 57 to 67v54
  36. Site contacts updated at 1 of 57 sitesv53
  37. Site details revised at 1 of 57 sitesv52
  38. Study sites: 54 to 57v51
  39. Site details revised at 1 of 54 sitesv50
  40. Study sites: 52 to 54v49
  41. Study sites revised (52)v48 See this version in full on ClinicalTrials.gov ↗
  42. Site details revised at 3 of 52 sitesv47
  43. Site contacts updated at 1 of 52 sitesv46
  44. Site details revised at 1 of 52 sitesv45
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Trial Details
NCT Number NCT05711940
Lead Sponsor COMPASS Pathways
Conditions Treatment Resistant Depression
Enrollment 572 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov